What is the most common systemic side effect associated with Brimonidine?

The most common systemic side effect associated with Brimonidine is dry mouth. This medication, which is an alpha-2 adrenergic agonist used primarily in the treatment of glaucoma, can lead to decreased saliva production as a result of its mechanism of action. When the alpha-2 receptors are activated, they can inhibit the release of neurotransmitters that stimulate saliva secretion, resulting in a sensation of dry mouth or xerostomia. This side effect can be particularly bothersome for patients, as adequate saliva is essential for oral health and comfort.

While other systemic effects can occur with Brimonidine, such as headache, drowsiness, and cardiovascular issues, they are not as commonly reported or significant in terms of overall prevalence compared to dry mouth. Understanding this side effect is crucial for managing patient care effectively, especially since it may impact adherence to the treatment regimen if not addressed.